Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Cell ; 183(6): 1496-1507.e16, 2020 12 10.
Artigo em Inglês | MEDLINE | ID: mdl-33171099

RESUMO

Antibodies are key immune effectors that confer protection against pathogenic threats. The nature and longevity of the antibody response to SARS-CoV-2 infection are not well defined. We charted longitudinal antibody responses to SARS-CoV-2 in 92 subjects after symptomatic COVID-19. Antibody responses to SARS-CoV-2 are unimodally distributed over a broad range, with symptom severity correlating directly with virus-specific antibody magnitude. Seventy-six subjects followed longitudinally to ∼100 days demonstrated marked heterogeneity in antibody duration dynamics. Virus-specific IgG decayed substantially in most individuals, whereas a distinct subset had stable or increasing antibody levels in the same time frame despite similar initial antibody magnitudes. These individuals with increasing responses recovered rapidly from symptomatic COVID-19 disease, harbored increased somatic mutations in virus-specific memory B cell antibody genes, and had persistent higher frequencies of previously activated CD4+ T cells. These findings illuminate an efficient immune phenotype that connects symptom clearance speed to differential antibody durability dynamics.


Assuntos
Anticorpos Antivirais/imunologia , Formação de Anticorpos , Linfócitos T CD4-Positivos/imunologia , COVID-19 , Imunoglobulina G/imunologia , Ativação Linfocitária , Mutação , COVID-19/genética , COVID-19/imunologia , Humanos , SARS-CoV-2/genética , SARS-CoV-2/imunologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa